FindTrial
Sign In

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2016-001519-19-FR
Enrollment
44
Registered
2016-08-01
Start date
2016-10-04
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 19.0 Level: SOC Classification code 10042613 Term: Surgical and medical procedures System Organ Class: 10042613 - Surgical and medical procedures

Interventions

Trade Name: Ropivacaïne 2.0 mg/mL Product Name: Ropivacaïne Pharmaceutical Form: Solution for injection INN or Proposed INN: ROPIVACAINE HYDROCHLORIDE CAS Number: 84057-95-4 Other descriptive name: R

Sponsors

Centre Hospitalier Départemental Vendée de la Roche sur Yon
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 8 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 36

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Contacts

Public ContactAUZANNEAU Lucie

Centre Hospitalier Départemental Vendée

lucie.auzanneau@chd-vendee.fr330251446380

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026